Roberto Chica Lab

@chicalab.bsky.social

Our research group at the University of Ottawa specializes in computational enzyme design. mysite.science.uottawa.ca/rchica/

We can design "static" binders routinely now, but design of "dynamic" shape-changing proteins has remained quite hard. Jeffrey Chang and I asked: why can't we couple small-molecule binding to shape change? After all, natural proteins do it every day. In a new preprint, we show how it can be done. 🧵

Join us! We are looking for a new team member (PhD student) with strong background in organic chemistry. 🙏 RETWEET (We want to recruit internationally) Organic chemistry meets #DirectedEvolution Highly interdisciplinary & passionate research group uni-bielefeld.hr4you.org/job/view/433...

Research Position (PhD) in organic chemistry and b...

<div style="text-align: justify;">The&nbsp; research&nbsp; group&nbsp; „Organic&nbsp; Chemistry&nbsp; and&nb...

uni-bielefeld.hr4you.org

Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1... 🧵🧪

Zero-shot design of drug-binding proteins via neural selection-expansion

Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...

biorxiv.org

Thrilled to take a break from doom and gloom to share our latest work collaborating with the DeGrado lab! We took a de novo designed protein, screened it for ligand binding using X-rays, and used the hits to evolve two wildly different functions: fluorescent turn-on and Kemp elimination catalysis. 🧵

A diagram illustrating the evolution of protein functionality through sequence and chemical space.

ABLE (bottom left): Depicted as a helical bundle binding the drug apixaban, labeled as a "specialist" in binding apixaban. Its binding site is shown as a filled cavity with the drug's structure.
ABLE as a generalist (center): After fragment screening, ABLE evolves to weakly bind various small molecule fragments, shown in a diverse array within the cavity. This transition highlights the exploration of chemical space.
FABLE (top right): Derived from fragment-inspired design, FABLE binds turn-on fluorophores. The binding site is reconfigured to fit fluorophores like Cou485, with their chemical structures displayed.
KABLE (bottom right): Another fragment-inspired evolution turns ABLE into KABLE, a Kemp eliminase. The structure of the substrate (5-nitrobenzisoxazole) is shown, with the binding site adapted for catalysis.
The axes represent "Sequence Space" (vertical) and "Chemical Space" (horizontal), emphasizing how the protein evolves through these dimensions to achieve specialized functions.
This schematic encapsulates the journey of ABLE from a specific binder to a generalist and then into two specialized proteins with distinct functionalities.

Bluetorial-A dream and a bit of a nightmare Serving as Editor-in-Chief at Science was fascinating. I greatly enjoyed working with talented and committed editorial, news, graphics, and production staff. But the inside look into scientific publishing and AAAS was also deeply disillusioning.

a cartoon says hey everybody an old man 's talking while bart simpson looks on

ALT: a cartoon says hey everybody an old man 's talking while bart simpson looks on

media.tenor.com

There is no "committee on science" that will impose a new order or set of incentives. No one is going to "fix" peer review or incentivize it differently in one fell swoop. We have to BE the change - the tools already exist for everyone at every level to make an impact and change the incentives

Harris Wang@harriswang.bsky.social · 2y ago

💡💥Here’s a modest proposal I’ve been pondering for a while on how to change the PEER REVIEW process and start more community-driven SCIENCE FUNDING. Lots of feedback/discussion welcomed! Other variants of the idea might exist already—not claiming originality. (a long 🧵) (1/9)